AG-20B-0023 anti-TRAIL-R2 (human), mAb (HS201)

Monoclonal Antibody

Purified from concentrated hybridoma tissue culture supernatant.

Recombinant human TRAIL-R2 (DR5).

Flow Cytometry
Functional Application: Inhibition (blocks TRAIL-R2 mediated killing if applied in solution).
Immunocytochemistry
Immunohistochemistry: (paraffin sections, 15µg/ml)
Immunoprecipitation

Human

Recognizes human TRAIL-R2. Does not cross-react with human TRAIL-R1, -R3 or -R4.

Protein G-affinity purified.

本產品短期保存請置於 4°C，長期保存建議分裝後存於 -20°C，可穩定保存至少一年，避免反覆凍融。

1. Caspase-10 is recruited to and activated at the native TRAIL and CD95 death-inducing signalling complexes in a FADD-dependent manner but can not functionally substitute caspase-8: M.R. Sprick, et al.; EMBO J. 21, 4520 (2002)
2. Mitogen-Activated Protein Kinase/Extracellular Signal-Regulated Kinase Signaling in Activated T Cells Abrogates TRAIL-Induced Apoptosis Upstream of the Mitochondrial Amplification Loop and Caspase-8: T.S. Soderstrom, et al.; J. Immunol. 169, 2851 (2002)
3. Bile acids stimulate cFLIP phosphorylation enhancing TRAIL-mediated apoptosis: H. Higuchi, et al.; J. Biol. Chem. 278, 454 (2003)
4. Proteasome inhibition results in TRAIL sensitization of primary keratinocytes by removing the resistance-mediating block of effector caspase maturation: M. Leverkus, et al.; Mol. Cell. Biol. 23, 777 (2003)
5. TNF-Related Apoptosis-Inducing Ligand Mediates Tumoricidal Activity of Human Monocytes Stimulated by Newcastle Disease Virus: B. Washburn, et al.; J. Immunol. 170, 1814 (2003)
6. Enhanced caspase-8 recruitment to and activation at the DISC is critical for sensitisation of human hepatocellular carcinoma cells to TRAIL-induced apoptosis by chemotherapeutic drugs: T.M. Ganten, et al.; Cell Death Differ. 11 Suppl 1, 86 (2004)
7. Casein kinase I attenuates tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by regulating the recruitment of fas-associated death domain and procaspase-8 to the death-inducing signaling complex: K. Izeradjene, et al.; Cancer Res. 64, 8036 (2004)
8. Fas-associated protein with death domain (FADD)-independent recruitment of c-FLIPL to death receptor 5: T.G. Jin, et al.; J. Biol. Chem. 279, 55594 (2004)
9. TRAIL regulates normal erythroid maturation through an ERK-dependent pathway: P. Secchiero, et al.; Blood 103, 517 (2004)
10. IFN{alpha}-stimulated neutrophils and monocytes release a soluble form of TNF-related apoptosis-inducing ligand (TRAIL/Apo-2 ligand) displaying apoptotic activity on leukemic cells: C. Tecchio, et al.; Blood 103, 3837 (2004)
11. cFLIPL inhibits tumor necrosis factor-related apoptosis-inducing ligand-mediated NF-kappaB activation at the death-inducing signaling complex in human keratinocytes: T. Wachter, et al.; J. Biol. Chem. 279, 52824 (2004)
12. Resistance to FasL and tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in Sezary syndrome T-cells associated with impaired death receptor and FLICE-inhibitory protein expression: E. Contassot, et al.; Blood 111, 4780 (2008)
13. TRAIL-R2-specific antibodies and recombinant TRAIL can synergise to kill cancer cells: M.H. Tuthill, et al.; Oncogene 34, 2138 (2015)
14. The TRAIL-Induced Cancer Secretome Promotes a Tumor-Supportive Immune Microenvironment via CCR2: T. Hartwig, et al.; Mol. Cell 65, 730 (2017)
15. TRAIL-receptor 2—a novel negative regulator of p53: A. Willms, et al.; Cell Death Dis. 12, 757 (2021)
16. NCTR25 fusion facilitates the formation of TRAIL polymers that selectively activate TRAIL receptors with higher potency and efficacy than TRAIL: Y. Wang, et al.; Cancer Chemother. Pharmacol. 88, 289 (2021)
17. Engagement of TRAIL triggers degranulation and IFNc production in human natural killer cells: J. Höfle, et al.; EMBO Rep. e54133 (2022)